share_log

Biomerica | 10-Q: Q1 2025 Earnings Report

Biomerica | 10-Q: Q1 2025 Earnings Report

Biomerica | 10-Q:2025財年一季報
美股SEC公告 ·  2024/10/16 05:04

Moomoo AI 已提取核心訊息

Biomerica reported Q1 FY2025 revenue of $1.81M, up 5% YoY from $1.71M, driven by a 190% surge in contract manufacturing sales to $339,000. However, net loss expanded to $1.32M from $1.13M last year, as gross margin declined to 16% from 24% due to one-time severance costs from workforce reduction.The company implemented significant cost-cutting measures, including a 15% workforce reduction in July 2024, while continuing commercialization of key products like inFoods IBS test and hp+detect H. pylori diagnostic test. R&D expenses decreased 37% to $297,000, reflecting strategic reallocation of resources and reduced clinical trials.Cash and equivalents stood at $2.82M as of August 31, 2024, down from $4.17M at May 31, 2024. Management acknowledged going concern risks and filed a shelf registration to raise up to $20M, while pursuing strategies to increase sales, reduce expenses and explore strategic alternatives to enhance shareholder value.
Biomerica reported Q1 FY2025 revenue of $1.81M, up 5% YoY from $1.71M, driven by a 190% surge in contract manufacturing sales to $339,000. However, net loss expanded to $1.32M from $1.13M last year, as gross margin declined to 16% from 24% due to one-time severance costs from workforce reduction.The company implemented significant cost-cutting measures, including a 15% workforce reduction in July 2024, while continuing commercialization of key products like inFoods IBS test and hp+detect H. pylori diagnostic test. R&D expenses decreased 37% to $297,000, reflecting strategic reallocation of resources and reduced clinical trials.Cash and equivalents stood at $2.82M as of August 31, 2024, down from $4.17M at May 31, 2024. Management acknowledged going concern risks and filed a shelf registration to raise up to $20M, while pursuing strategies to increase sales, reduce expenses and explore strategic alternatives to enhance shareholder value.
Biomerica報告了2025財年第一季度的營業收入爲181萬美元,比171萬美元增長了5%,主要受合同製造業銷售激增190%至339,000美元的推動。然而,淨虧損擴大至132萬美元,去年爲113萬美元,毛利率因裁員的一次性遣散費用從24%下降至16%。該公司實施了重大削減開支措施,包括在2024年7月裁減15%的員工,同時繼續推進inFoods IBS測試和hp+detect H. pylori診斷測試等關鍵產品的商業化。研發費用減少37%,至297,000美元,反映出資源的戰略重新配置和減少了臨牀試驗。截至2024年8月31日,現金及現金等價物爲282萬美元,低於2024年5月31日的417萬美元。管理層承認存在持續經營風險,並提交了一項貨架註冊以籌集最多2000萬美元,同時採取措施增加銷售、減少開支,並探索戰略替代方案以提高股東價值。
Biomerica報告了2025財年第一季度的營業收入爲181萬美元,比171萬美元增長了5%,主要受合同製造業銷售激增190%至339,000美元的推動。然而,淨虧損擴大至132萬美元,去年爲113萬美元,毛利率因裁員的一次性遣散費用從24%下降至16%。該公司實施了重大削減開支措施,包括在2024年7月裁減15%的員工,同時繼續推進inFoods IBS測試和hp+detect H. pylori診斷測試等關鍵產品的商業化。研發費用減少37%,至297,000美元,反映出資源的戰略重新配置和減少了臨牀試驗。截至2024年8月31日,現金及現金等價物爲282萬美元,低於2024年5月31日的417萬美元。管理層承認存在持續經營風險,並提交了一項貨架註冊以籌集最多2000萬美元,同時採取措施增加銷售、減少開支,並探索戰略替代方案以提高股東價值。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息